Press Releases

GlobeNewswire, Inc.

BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that...

EIN Presswire

UK, UNITED KINGDOM, August 11, 2026 /⁨EINPresswire.com⁩/ -- Blue Light Transition, founded by retired Detective Inspector Janet Barr and recruitment professional Tommy Jones, has launched the Badge to Boardroom programme — a six-step career...

EIN Presswire

CDAO Financial Services & Insurance UK Returns to London, Bringing Together the Leaders Shaping the Future of Data, Governance, and Analytics LONDON, UNITED KINGDOM, August 11, 2026 /⁨EINPresswire.com⁩/ -- As financial institutions face growing...

EIN Presswire

LONDON, UNITED KINGDOM, August 11, 2026 /⁨EINPresswire.com⁩/ -- As financial institutions accelerate enterprise AI adoption, the AI in Finance Summit London returns for its 11th edition, bringing together senior AI, data, technology, and...

GlobeNewswire, Inc.

~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue...

EIN Presswire

The Portfolio Executives opens registration for its free Fractional Executive Jumpstart programme as UK job cuts reshape senior careers.

GlobeNewswire, Inc.

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year FY 2026 net product revenue guidance increased to $140 - $150 million Gross margin increased in Q2...

GlobeNewswire, Inc.

Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France New clinical data on HMB-002 demonstrated 2.4-fold...

GlobeNewswire, Inc.

Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology Association (EHA) 2026 Congress Further Support...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics,...

GlobeNewswire, Inc.

London, UK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- As the global economy continues to evolve, individuals and businesses are increasingly looking for intelligent financial solutions that can simplify decision-making, improve efficiency, and support...

GlobeNewswire, Inc.

HONG KONG, Aug. 11, 2026 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial...

GlobeNewswire, Inc.

LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- More than 90% of young people would consider an apprenticeship over a university degree, a new survey from the skills charity Enginuity has revealed.

GlobeNewswire, Inc.

STILLWATER, Okla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), (USAR), a rare earth, critical minerals and advanced materials company, today announced its financial and operational results for the second...

GlobeNewswire, Inc.

OMAHA, Neb., Aug. 10, 2026 (GLOBE NEWSWIRE) -- On August 10, 2026, Greystone Housing Impact Investors LP (NYSE: GHI) (the “Partnership”) announced financial results for the three months ended June 30, 2026. The Partnership also announced it will...

GlobeNewswire, Inc.

One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight...

GlobeNewswire, Inc.

Continued Revenue Growth and Disciplined M&A Execution in First Half of 2026; Raises Full Year 2026 Guidance to Reflect Recent Acquisitions H1 2026 revenue growth of 16.3% with organic revenue growth of 4.4%, compared to H1 2025 Completed one...

GlobeNewswire, Inc.

- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby...

GlobeNewswire, Inc.

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in...

GlobeNewswire, Inc.

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as...